The results presented in this study also suggest high promise of targeting PDEF and CEACAM6 in breast cancer, independent of and/or in conjunction with the existing ER and Her2 targeted treatments of hormone receptor-positive and Her2 over expressing tumors. Here, ERBB2 is linked to breast carcinoma.